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Abstract Recent experimental data show that some human ge- 
netic diseases are due to mutations in proteins which influence 
their trafficking and lead to retaining of proteins in the endoplas- 
mic reticulum or their unproper processing. In this paper a hy- 
pothesis is proposed that these mutations are connected with an 
incomplete protein folding, blocking it at the stage of the kinetic 
molten globule or even earlier. If so, the specific drugs against 
these diseases may be ligands and other factors which facilitate 
the correct protein folding. 
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1. Introduction 
It has been shown recently that some point mutations in a 
number of proteins lead to genetic diseases. These mutations 
mislocate proteins in a cell leading to the loss of their function 
(see [1] for review). What is the structural basis for this mislo- 
cation? The intriguing possibility is that the molten globule or 
similar state of protein molecules [2,3] may be involved in this 
process. 
2. Some point mutations transform proteins into the molten 
globule state 
mutants of G protein of vesicular stomatisis virus with altered 
glycosylation sites also fold in a way different from that of the 
native protein. These mutants usually have non-native di- 
sulphide bonds and are retained in the endoplasmic reticulum 
(ER) in a complex with chaperones. 
Lim et al. [12] have investigated point mutations in a non- 
polar core of the N-terminal domain of A-repressor. Substitu- 
tions of non-polar groups by polar ones (Leu-18~Asn, Val- 
36-~Asn and Val-36--*Asp) drastically change the properties of 
mutant proteins. These proteins lose activity, do not bind anti- 
bodies against he native protein, have no cooperative t mper- 
ature melting, their NMR resonances become broad and less 
dispersed than in the native protein. However, they retain a lot 
of their native far UV CD ellipticity, and their NMR spectra 
still have resonances well shifted from their random coil posi- 
tions. The authors concluded that folding of these mutant pro- 
teins is blocked in the molten globule state. 
Quite recently Horowitz and his group [13,14] have shown 
that replacements of Lys-249 or Arg-186 change specificity, 
stability and structural state of rhodanase. Mutant proteins 
have an increased hydrophobic surface, because they bind 
ANS, and quenching of their Trp fluorescence by acrylamide 
is increased. It may be suggested that these mutant proteins are 
in the molten globule state. 
These examples how that even a single point mutation can 
transform the native protein into the molten globule. 
There are in vitro experimental data showing that point mu- 
tations can hinder last stages of protein folding and arrest 
protein folding intermediates under physiological conditions. 
The first evidence was obtained by King and his col- 
laborators [4,5], They have shown that some thermosensitive 
mutants of tailspike endorhamnosidase of phage P22 cannot 
fold correctly at non-permissive t mperature (39-42°C). How- 
ever, at lower temperature (30°C) some of these mutants can 
fold into the native structure and assemble correctly [6]. When 
folded, they remain stable at 42°C. It means that the lack of 
intracellular folding is due to the decreased stability of folding 
intermediates rather than of native proteins [7,8]. 
Craig et al. have reported [9] that two point mutations in 
fl-lactamase (Thr-40--*Ile and Asp-146-~Asn) prevent he pro- 
tein from the correct folding and trap it into an intermediate 
state. 
Machamer et al. [10,11] have shown that thermosensitive 
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3. Some point mutations associated with genetic diseases lead to 
a mislocation of proteins in a cell 
3.1. Cystic fibrosis transmembrane conductance r gulator 
Cystic fibrosis is a human genetic disease caused by muta- 
tions in cystic fibrosis transmembrane conductance regulator 
(CFTR) [15-17]. In 70% of cases this disease is associated with 
a deletion of Phe-508 (mutant AF 508). Newly synthesized 
CFTR forms a transient complex with chaperone hsp70. The 
wild type protein dissociates from this complex and is trans- 
ported to the Golgi with a subsequent traffic to a plasma mem- 
brane [15]. As a contrast, the mutant DF 508 remains in a 
complex with hsp70 in the ER and is rapidly degraded in a 
pre-Golgi non-lysosomal compartment [15]. It has been pro- 
posed that the deletion of Phe-508 perturbs protein folding, 
leads to its tighter binding to hsp70, and to retention of the 
mutant in the ER implicating the defect of its trafficking. The 
idea that this mutant has a defective folding is supported by a 
temperature s nsitivity of this mutant [16,17]. 
Thus, hsp70 can discriminate between ormal and mutant 
forms of CFTR. These [15] and other [11,18] data suggest that 
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associated with some genetic diseases. 
a chaperone performs quality control during the biosynthesis 
of plasma-membrane and secreted proteins. Mutants which 
cannot be released from chaperones remain in the ER where 
they are degraded [11,15,18] instead of being transported from 
the ER to reach their destination i  a cell. 
3.2. oG-antitrypsin 
Another example is emphysema and chronic liver diseases, 
caused by the insufficiency of 0~l-antitrypsin (AAT), the serine 
protease inhibitor (see [1,19] and references therein). Under the 
mild denaturing conditions (1 M GdmC1 and 37M1°C) AAT 
has a tendency to aggregate presumably due to the moving of 
14-residues loop which contains the reaction inhibiting site [20]. 
The Z mutant of cO-antitrypsin has Glu-342 substituted by 
Lys [20]. Glu-342 is located at the beginning of the reactive 
loop, which is stabilized by salt bridge between Glu-342 and 
Lys-290 in the wild type protein. The mutation Glu-342~Lys 
leads to disruption of the salt bridge and makes this loop more 
flexible and E-sheet more 'open'. As a result, the reactive loop 
can interact with other AAT molecules being in similar 'open' 
conformation. This promotes AAT aggregation i the ER even 
under physiological conditions [20] and probably also its asso- 
ciation with chaperones [19,21]. Thus, in this case we again face 
with a mislocation of protein in a cell. 
3.3. Other proteins 
A similar mechanism ay operate also in the pathogenesis 
of some other diseases, including for example hypercholesterol- 
emia, caused by mutation on the low density lipoprotein (LDL) 
receptor, responsible for the serum cholesterol level. Class 2 
mutations of LDL receptor (50% of all cases) results in a pro- 
tein which cannot be secreted from the ER [1,22,23]. Another 
example is the Tay-Sachs disease which is connected with muta- 
tions in lysosomal enzymes, which dimeric forms are finally 
processed in lysosomes. At least one of these mutations results 
in defective protein trafficking: the mutant of~-hexosaminidase 
is not secreted from the ER, not processed in lysosomes, and 
is degraded in the ER [1,24]. 
The list of mutant proteins which mistocation leads to differ- 
ent types of genetic diseases is given in Table 1. 
4. Hypothesis 
It was predicted [25] and confirmed experimentally [26-30] 
that chaperones recognize proteins in the molten globule (or a 
little more expanded [29,30]) state. It supports the idea that 
chaperones bind newly synthesized protein chains trapping 
them in the molten globule state or even in the earlier kinetic 
intermediate. On the other hand, there is also some direct evi- 
Table 1 
Some point mutations in proteins and related genetic diseases 
Protein Mutations Disease Ref. 
Cystic fibrosis transmembrane conductance r gulator 
1-antitrypsin 
Low density lipoprotein receptor 
fl-hexosaminidase (~-subunit) 
Deletion of F508 
Glu342~Lys 
Class 2 
Deletion of cytosine at position 1510 
of the mRNA coding sequence 
Cystic fibrosis [15] 
Emphysema, chronic liver diseases [20] 
Familial hypercholesterolemia [22,23] 
Tay-Sachs disease [24] 
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dence that a protein should be transformed into the molten 
globule state before its degradation i vivo (see [3] for a review). 
Thus mutations which block protein folding in the molten glob- 
ule or in the earlier kinetic intermediate can lead to dislocation 
of aprotein in a cell and facilitate its degradation. 
We suggest hat mutations which promote some genetic dis- 
eases connected with an intracellular mistrafficking of proteins 
belong to the mutations which inhibit the last stage of protein 
folding. As a result, mutant proteins are trapped in the molten 
globule or in another kinetic intermediate. This does not allow 
mutant proteins to use a normal intracellular pathway and 
leads to their mislocation and subsequent degradation. 
Thus we propose the hypothesis that incomplete protein Jold- 
ing blocked at the kinetic molten globule or another intermediate 
state leads to mislocation of proteins in a cell and may provoke 
genetic diseases. Fig. 1 illustrates this hypothesis. It shows that 
a wild type protein is bound to a chaperone just after its biosyn- 
thesis, then is released in the ER, and is transported to a cell 
membrane or to another cell compartment where it normally 
functions. On the contrary, a mutant protein which is in the 
molten globule or another denatured state cannot been released 
from chaperone and therefore is retained in the ER where it is 
later degraded. 
Quite recently experimental data on tumor suppressor pro- 
tein p53 appeared which seem to be consistent with our hypoth- 
esis. Among many different functions of this protein in a cell 
there is the preventing from cancer. Mutations of p53 which 
lead to inactivation of its tumor suppressor activity contribute 
to development of many human cancers (see [31-33] for refer- 
ences). One class of these mutations inhibits binding p53 to 
DNA, while another class leads to denaturation of this protein 
[32]. In fact, mutants of the second class bind antibodies specific 
to denatured rather than to native p53 and are highly sensitive 
to proteolytic enzymes. 
The mutants of the second class (for example, replacements 
of Arg-175 and Val-143) are bound by heat shock proteins 
hsp70 [34,35], and it was also shown that some of these mutants 
are mislocated in a cell [34]. 
Thus, at least in one case mutations of a protein lead to its 
denaturation and to its mislocation in a cell, which is consistent 
with our hypothesis. Of course, a lot of work should be per- 
formed to check this hypothesis by direct structural data. 
If this hypothesis i correct, a study of the influence of ligands 
and other factors on protein folding in vitro may lead to a 
rational design of new drugs against some genetic diseases. An 
example of these drugs can be antibodies against the native 
structure as well as other templates which might facilitate pro- 
tein folding. In another case, these may be small specific pep- 
tides which can compete with flexible parts of protein molecules 
for intermolecular interactions [20]. 
This hypothesis emphasizes how important it is to study the 
non-native states of proteins in a cell for different biological 
and even medical purposes including the treatment of some 
genetic diseases. 
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